| Intratumor heterogeneity and branched evolution revealed by multiregion sequencing M Gerlinger, AJ Rowan, S Horswell, J Larkin, D Endesfelder, E Gronroos, ... New England journal of medicine 366 (10), 883-892, 2012 | 8612 | 2012 |
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ... Nature genetics 46 (3), 225-233, 2014 | 1369 | 2014 |
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution EC De Bruin, N McGranahan, R Mitter, M Salm, DC Wedge, L Yates, ... Science 346 (6206), 251-256, 2014 | 1246 | 2014 |
| Intratumor heterogeneity: seeing the wood for the trees TA Yap, M Gerlinger, PA Futreal, L Pusztai, C Swanton Science translational medicine 4 (127), 127ps10-127ps10, 2012 | 600 | 2012 |
| How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine M Gerlinger, C Swanton British journal of cancer 103 (8), 1139-1143, 2010 | 534 | 2010 |
| Classifying the evolutionary and ecological features of neoplasms CC Maley, A Aktipis, TA Graham, A Sottoriva, AM Boddy, M Janiszewska, ... Nature Reviews Cancer 17 (10), 605-619, 2017 | 390 | 2017 |
| Cancer evolution and the limits of predictability in precision cancer medicine KA Lipinski, LJ Barber, MN Davies, M Ashenden, A Sottoriva, M Gerlinger Trends in cancer 2 (1), 49-63, 2016 | 294 | 2016 |
| Cancer: evolution within a lifetime M Gerlinger, N McGranahan, SM Dewhurst, RA Burrell, I Tomlinson, ... Annual review of genetics 48 (1), 215-236, 2014 | 236 | 2014 |
| Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer A Woolston, K Khan, G Spain, LJ Barber, B Griffiths, R Gonzalez-Exposito, ... Cancer cell 36 (1), 35-50. e9, 2019 | 212 | 2019 |
| SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair N Kanu, E Grönroos, P Martinez, RA Burrell, X Yi Goh, J Bartkova, ... Oncogene 34 (46), 5699-5708, 2015 | 187 | 2015 |
| Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers S Gulati, P Martinez, T Joshi, NJ Birkbak, CR Santos, AJ Rowan, ... European urology 66 (5), 936-948, 2014 | 173 | 2014 |
| Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas M Gerlinger, SA Quezada, KS Peggs, AJS Furness, R Fisher, T Marafioti, ... The Journal of pathology 231 (4), 424-432, 2013 | 155 | 2013 |
| Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast … N Juul, Z Szallasi, AC Eklund, Q Li, RA Burrell, M Gerlinger, V Valero, ... The lancet oncology 11 (4), 358-365, 2010 | 147 | 2010 |
| Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications M Gerlinger, JW Catto, TF Orntoft, FX Real, EC Zwarthoff, C Swanton European urology 67 (4), 729-737, 2015 | 137 | 2015 |
| Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target M Gerlinger, CR Santos, B Spencer‐Dene, P Martinez, D Endesfelder, ... The Journal of pathology 227 (2), 146-156, 2012 | 136 | 2012 |
| Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop J Kumbrink, M Gerlinger, JP Johnson Journal of Biological Chemistry 280 (52), 42785-42793, 2005 | 130 | 2005 |
| Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment A Newey, B Griffiths, J Michaux, HS Pak, BJ Stevenson, A Woolston, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 113 | 2019 |
| Parallel evolution of tumour subclones mimics diversity between tumours P Martinez, NJ Birkbak, M Gerlinger, N McGranahan, RA Burrell, ... The Journal of pathology 230 (4), 356-364, 2013 | 102 | 2013 |
| Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer M Lawler, D Alsina, RA Adams, AS Anderson, G Brown, NS Fearnhead, ... Gut 67 (1), 179-193, 2018 | 88 | 2018 |
| Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference DSW Tan, M Gerlinger, BT Teh, C Swanton European Journal of Cancer 46 (12), 2166-2177, 2010 | 88 | 2010 |
